Tetrahydrocannabinol: From Pot to Prescription?
Authors: JOHN LASZLO
Journal: Annals of Internal Medicine (1979)

Editorials1 December 1979Tetrahydrocannabinol: From Pot to Prescription?JOHN LASZLO, M.D.JOHN LASZLO, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-91-6-916 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Excerpt"Let the jury consider the verdict," the King said, for about the twentieth time that day. "No, no!" said the Queen. "Sentence first—verdict afterwards." (1)It would be a challenge even to Alice to find a way through the issues of science, regulation, and public welfare in the topsy-turvy world of medicinal uses of marijuana and its derivatives.An elegant study reported in this issue by Chang and associates (2) tested the efficacy of a purified synthetic derivative of marijuana, delta-9-tetrahydrocannabinol (THC), as an antiemetic for a group of young patients receiving methotrexate treatment for osteogenic sarcoma. During repeated courses...References1. CARROLL L. Alice in Wonderland. Garden City, New York: International Collectors Library; p. 134. Google Scholar2. CHANG A, SHILING D, and STILLMAN R. Delta-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate: a prospective, randomized evaluation. Ann Intern Med. 1979;91:819-24. LinkGoogle Scholar3. SALLAN S, ZINBERG N, and FREI E. Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med. 1975;293:795-7. CrossrefMedlineGoogle Scholar4. REGELSON W, BUTLER J, SCHULZ J, KIRK T, PECK L, and GREEN M. Delta-9-tetrahydrocannabinol as an effective antidepressant and appetite-stimulating agent in advanced cancer patients. In: BRAUDE MC, SZARA S, eds. The Pharmacology of Marihuana. New York: Raven Press; 1976. Google Scholar5. FRYTAK S, MOERTEL C, and O'FALLON J. Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy: a comparison with prochlorperafine and a placebo. Ann Intern Med. 1979;91:825-30. LinkGoogle Scholar6. LUCAS S and LASZLO J. Delta-9-tetrahydrocannabinol for refractory vomiting induced by cancer chemotherapy. JAMA. In press. Google Scholar7. HERMAN T, EINHORN L, and JONES S. Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med. 1979;300:1295-7. CrossrefMedlineGoogle Scholar8. Marijuana and synthetic THC; scheduling of controlled substances. FED REGIST. 1979;44:36123-8. Google Scholar9. NIGHTINGALE S and PERRY S. Marijuana and heroin by prescription? Recent developments at the state and federal levels. JAMA. 1979;241:373-5. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: JOHN LASZLO, M.D.Affiliations: Comprehensive Cancer Center Duke University Medical Center Durham, North Carolina PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byFCarbohydratesDelta-9-Tetrahydrocannabinol in Cancer Chemotherapy: Research Problems and IssuesMICHAEL P. CAREY, B.S., THOMAS G. BURISH, Ph.D., DEAN E. BRENNER, M.D.A Critical Review of the Safety and Antiemetic Efficacy of Delta-9-TetrahydrocannabinolLevonantradol for Chemotherapy-Induced Emesis: Phase I-II Oral AdministrationCannabinoids in the Management of Severe Nausea and Vomiting from Cancer Chemotherapy. Some Additional ConsiderationsSocial drugsCANNABIS: A MEDICAL QUESTION? 1 December 1979Volume 91, Issue 6Page: 916-918KeywordsMarijuanaMethotrexatePatientsSarcoma ePublished: 1 December 2008 Issue Published: 1 December 1979 PDF downloadLoading ...